On May 8, 2023, Jean-Michel Halfon informed Teva Pharmaceutical Industries Ltd. that in light of personal reasons, he will resign from Teva's Board of Directors, effective immediately. Mr. Halfon has served as a director on the Board since 2014, as chair of the Board's HR and Compensation Committee and more recently as chair of the Compliance Committee. As provided in Teva's Notice of 2023 Annual Meeting of Shareholders and Proxy Statement, filed with the Securities and Exchange Commission on April 19, 2023, Mr. Halfon is not standing for re-election at Teva's upcoming annual meeting of shareholders on June 15, 2023.

Mr. Halfon's decision to resign as a director was not due to any disagreements with Teva.